During Tuesday’s Afternoon trade, Shares of Tripadvisor Inc (NASDAQ:TRIP), lost -1.51% to $72.39.
The Independent Traveler, Inc. – publisher of three leading online travel sites, and part of the TripAdvisor Media Group – declares the appointment of Mike Ewing as general manager. Ewing will oversee the online publisher’s three brands – Cruise Critic, Family Vacation Critic and IndependentTraveler.com.
Preceding to joining The Independent Traveler, Inc., Ewing held administration roles at LogMeIn, Vistaprint, and Monster.com. Ewing’s professional career comprises time in the US in addition to time abroad with responsibility for large geographic regions. An avid traveler, Ewing has been around the world while managing global teams focused on consumer, media and B2B businesses. Ewing is a regular speaker and contributor on topics as wide-ranging as sales and marketing, building high-performance teams and venture funding.
TripAdvisor, Inc. operates as an online travel company. The company operates through two segments, Hotel and Other. Its travel research platform aggregates reviews and opinions about accommodations, destinations, activities and attractions, and restaurants that enable consumers to plan and book hotels, vacation rentals, flights, activities and attractions, and restaurants.
Shares of Parker-Hannifin Corporation (NYSE:PH), declined -0.21% to $112.40, during its Afternoon trading session.
Invenshure, LLC, a technology incubator and venture catalyst, recently declare that Parker Hannifin Corporation ( PH) accomplished a noteworthy minority equity investment in Exosite LLC, one of Invenshure’s portfolio companies. In addition, through a preferred supplier agreement, Parker Hannifin and Exosite will expand their partnership, which began in 2013 with technology partnershipto deploy Internet of Things (IoT) solutions across several of its global operating divisions.
With annual sales surpassing $13 billion in fiscal year 2014, Parker Hannifin is the world’s leading diversified manufacturer of motion and control technologies and systems, providing precision-engineered solutions for a wide variety of mobile, industrial, and aerospace markets.
Exosite, headquartered in Minneapolis, MN, is a leading developer of cloud-based solutions that enable customers to connect smart devices to the Internet for remote control, monitoring, and business analytics. Exosite’s software solutions are highly scalable, customizable, secure, and reliable. These tools accelerate the time to market for customers building IoT businesses.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. It operates through two segments, Diversified Industrial and Aerospace Systems. The Diversified Industrial segment provides pneumatic, fluidic, and electromechanical components and systems; filters, systems, and diagnostics solutions to monitor and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors, which control, transmit, and contain fluid; hydraulic components and systems for builders and users of industrial and mobile machinery and equipment; critical flow components for process instrumentation, healthcare, and ultra-high-purity applications, in addition to components for use in refrigeration and air conditioning systems, and in fluid control applications for processing, fuel dispensing, beverage dispensing, and mobile emissions; and static and dynamic sealing devices.
Cytori Therapeutics Inc Cytori Therapeutics Inc(NASDAQ:CYTX (NASDAQ:CYTX), during its Tuesday’s Afternoon trading session gained 2.79% to $0.394.
Cytori Therapeutics (CYTX) declared its second quarter financial results and offered updates on its corporate activity and clinical development.
Cytori continued to reduce its operating cash burn, spending about $4.8 million in the second quarter 2015, contrast to $9.2 million in Q2 2014. Second quarter 2015 net income allocable to common stockholders was $4.5 million (or a net loss of $8.7 million and $0.06 per share when not taking into account a non-cash charge of $13.1 million related to the change in fair value of warrant liabilities) contrast to $11.8 million (or $0.15 per share) for the same period in 2014. Cytori ended the second quarter of 2015 with $23.8 million of cash and cash equivalents.
Selected Q2 Highlights:
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China – April 2015
Cytori received initial purchase order of Celution devices and 1,100 consumable sets from Lorem Vascular, our Chinese Licensee – April 2015
Cytori was granted orphan drug status for treatment of scleroderma in European Union – April 2015
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions.
Finally, IMS Health Holdings Inc (NYSE:IMS), gained 0.13%, to $31.13.
IMS Health Holdings, Inc. (IMS) declared the launch of an underwritten, secondary public offering of 20,000,000 shares of its common stock by certain of its existing shareholders associated with TPG Global, LLC, Canada Pension Plan Investment Board and Leonard Green & Partners, L.P. (the “Selling Shareholders”). IMS Health is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders.
J.P. Morgan and Morgan Stanley are acting as the joint book-running managers.
IMS Health Holdings, Inc. provides information and technology services to healthcare industry worldwide. Its principal products comprise national information offerings that provide performance metrics related to the sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity through multiple channels; and sub-national offerings, which offer information related to the measurement of sales at the regional, zip code, and individual prescriber level.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
